ClinicalTrials.gg
RecruitingNCT07665190RESERVE-HCUpdated Jul 16, 2026

Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma

A Phase 2 interventional study of Becotatug Vedotin and Pucotenlimab in Hypopharyngeal Squamous Cell Carcinoma, sponsored by Tianjin Medical University Cancer Institute and Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Tianjin Medical University Cancer Institute and Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing becotatug vedotin in Squamous Cell Carcinoma of Head and Neck — 15 open to participants now, 15 under way, 2 of them phase 3. becotatug vedotin · Squamous Cell Carcinoma of Head and Neck.

Planned enrollment
8th of 16
52 · median 52
Started
2026
with 11 others
Phase 2
13 of 16
12 open now
Primary completion
2027-10
later than 4 of 14 live
Registered
10th of 16
by date
Lead sponsor
1 of 16
Tianjin Medical University Cancer Institute and Hospital

Among the 16 studies testing becotatug vedotin in Squamous Cell Carcinoma of Head and Neck, this one is the 8th largest by planned enrollment, is one of 12 that started in 2026, is one of 13 in phase 2, reaches primary completion later than 4 of the 14 other live ones, and was the 10th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

15 of the 16 studies testing becotatug vedotin in Squamous Cell Carcinoma of Head and Neck are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

About becotatug vedotin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing becotatug vedotin in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

This clinical trial aims to evaluate the efficacy and safety of Becotatug Vedotin (EGFR-ADC) in combination with Pucotenlimab(Anti-PD-1 Monoclonal Antibody) as neoadjuvant therapy for patients with Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma.

The primary objective is the pathological complete response(pCR)rate following neoadjuvant therapy. The secondary objective includes the major pathological response(MPR)rate following neoadjuvant therapy, the objective response rate (ORR), Organ preservation rate, Surgery postponement rate, event-free survival (EFS), overall survival(OS), and safety.

Read the detailed description

This study is a multicenter, phase II clinical trial of neoadjuvant Becotatug Vedotin (EGFR-ADC) combined with Pucotenlimab (Anti-PD-1 monoclonal antibody) in patients with resectable locally advanced hypopharyngeal squamous cell carcinoma. Eligible participants will receive Becotatug Vedotin plus Pucotenlimab as preoperative neoadjuvant therapy, intravenous infusion every 3 weeks (Q3W) for 3 cycles.Tumor assessment will be performed after two cycles of neoadjuvant treatment. If, upon evaluation by the investigator, participants achieve a complete response (CR) based on radiographic assessment after two cycles, they may proceed directly to radical surgical resection. In the event of disease progression, severe adverse events, or intolerable toxicity during the neoadjuvant phase, the investigator may decide to discontinue neoadjuvant therapy and initiate radical therapy.

03

Conditions studied

  • Hypopharyngeal Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥ 18, male or female;
  2. Histopathologically confirmed Hypopharyngeal Squamous Cell Carcinoma;
  3. Surgically resectable, Clinical Stage III or IV and no distant (AJCC 8th edition);

3. Measurable primary lesions per v1.1; 5.Treatment-naive (no prior anti-tumor therapy for current disease); 6. performance status 0-1; 7.Estimated >= 3 months; 8.Have adequate organ function as defined by laboratory parameters; 9.No to chemotherapy, targeted therapy, or immunotherapy; 10.No history of immune-related diseases; 11.No uncontrolled pneumonia or pulmonary infection; 12.Female participants of must agree to use effective during the trial; A serum or urine pregnancy test must be negative within 72 hours prior to the start of chemotherapy; 13.The subject is volunteer to participate, and the subject must signed an form (ICF), indicating that it understands the purpose of this study and the required procedures, and is willing to participate in the study. Subjects must be willing and abide by prohibition and restrictions specified in the research program; Subjects are willing and able to follow the trial and follow-up procedures.

Exclusion criteria

Exclusion Criteria:

  1. Patients with distant ;
  2. Patients with uncontrolled severe medical conditions;
  3. Patients with a history of allergy or to any component of monoclonal antibody therapies;
  4. Uncontrolled cardiac clinical symptoms or diseases;
  5. Occurrence of severe infection ( Grade > 2) within 4 weeks prior to the first dose of the study drug;
  6. Unexplained fever > 38.5°C during the screening period or before the first dose;
  7. Active disease or a history of autoimmune disease;
  8. History of immunodeficiency, or a history of organ transplantation or bone marrow transplantation;
  9. Patients with untreated chronic , or chronic hepatitis B virus (HBV) DNA exceeding 500 IU/mL, or patients with active virus (HCV) must be excluded;
  10. History of interstitial lung disease;
  11. Patients with active pulmonary tuberculosis infection identified by medical history or CT scan;
  12. Patients who have received any of the following treatments:

    A. Receipt of any drug or anti-cancer therapy within 4 weeks prior to the first dose of the study drug; B. Requirement for systemic treatment with (daily dose > 10 mg prednisone equivalent) or other medications within 2 weeks prior to the first dose of the study drug.; C. Prior vaccination with an anti-tumor vaccine or receipt of a within 4 weeks prior to the first dose of the study drug; D. Major surgery or significant traumatic injury within 4 weeks prior to the first dose of the study drug; E. Concurrent enrollment in another clinical study;

  13. Dementia, altered mental status, or any psychiatric condition that would interfere with understanding or providing or completing questionnaires;
  14. Subjects with peripheral neuropathy ≥ Grade 2 according to CTCAE V5.0;
  15. History of allergy or hypersensitivity to any component of the study treatment;
  16. History of a primary other than head and neck squamous cell carcinoma within the previous 5 years;
  17. Requirement for concurrent treatment with other anti-tumor therapies;
  18. Patients deemed unsuitable for enrollment by the investigator;
  19. Pregnant or breastfeeding women.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Combination Therapy with Becotatug Vedotin and Pucotenlimab

    Drug: Becotatug Vedotin and Pucotenlimab

Interventions

  • DrugBecotatug Vedotin and Pucotenlimab

    Drug pages: Becotatug vedotinStudies of Becotatug vedotinBecotatug vedotin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PucotenlimabStudies of PucotenlimabPucotenlimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Neoadjuvant therapy: Becotatug Vedotin is dosed based on the participant's body weight. In this study, the dosing regimen is 2.3 mg/kg, administered via intravenous infusion on Day 1 of each cycle, once every 3 weeks (Q3W), for a total of 3 treatment cycles. The infusion time for Becotatug Vedotin should be no less than 60min, and it is recommended to be controlled within 60 to 90min. Pucotenlimab is administered at a fixed dose of 200 mg per infusion, via intravenous infusion on Day 1 of each cycle, once every 3 weeks (Q3W), for a total of 3 treatment cycles, with an infusion duration of 60min (±15 min). Becotatug Vedotin and Pucotenlimab are administered on the same day, Pucotenlimab is given first, followed by Becotatug Vedotin, with an interval of no less than 30min between the two infusions.

    Also known as: Becotatug Vedotin(MRG003), Pucotenlimab(HX008)

06

What researchers measure

Primary outcomes

  1. Pathological Complete Response(pCR) Rate

    The proportion of participants with no residual tumor cells in the resected primary tumor specimen after the completion of neoadjuvant therapy.

    Time frame: At the time of surgery

Secondary outcomes

  1. Major Pathological Response(MPR) Rate

    The proportion of participants who achieve a major pathological response, defined as residual viable tumor cells ≤ 10% in the resected primary tumor specimen following neoadjuvant therapy.

    Time frame: At the time of surgery

  2. Objective Response Rate(ORR)

    The proportion of participants who achieve a complete response (CR) or partial response (PR) as assessed by RECIST version 1.1 after completion of neoadjuvant therapy.

    Time frame: After 2 cycles or 3 cycles of neoadjuvant therapy

  3. Event-Free Survival (EFS)

    The time from the start of study treatment to the first occurrence of any of the following events, including but not limited to: disease progression precluding surgical treatment, local recurrence or distant metastasis, or death from any cause.

    Time frame: From start of study treatment up to approximately 3 years

  4. Overall Survival(OS)

    The time from the start of study treatment to death from any cause.

    Time frame: From start of study treatment up to approximately 5 years

  5. Organ Preservation Rate

    The proportion of participants in whom the surgical approach is optimized or the extent of surgery is reduced after neoadjuvant therapy, as determined by experienced surgeons comparing the feasible surgical approach based on baseline tumor assessment prior to neoadjuvant therapy with the feasible surgical approach after completion of neoadjuvant therapy.

    Time frame: At the time of surgery

  6. Surgery Postponement Rate

    The proportion of subjects who did not undergo radical surgery within 6 weeks after the last dose of neoadjuvant therapy.

    Time frame: 6 weeks after neoadjuvant therapy

  7. Adverse Events (AEs)

    Incidence, severity, and relationship to treatment of adverse events, as assessed by CTCAE criteria.

    Time frame: From first dose of study treatment to 1 month after the last dose

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Oct 2027, 15 months later.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 15 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2026
First posted
Jun 24, 2026
StartEst.
Jul 1, 2026
Primary completionEst.
Oct 31, 2027
CompletionEst.
Dec 31, 2030
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07665190
Responsible party
Sponsor
First posted
Jun 24, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Oct 31, 2027 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Jul 16, 2026

Study contacts

Xudong Wang
Contact
wxd.1133@163.com
86+02223340123-3130
Hongling Wang
Contact
wanghongling86@163.com
86+02223340123-3130

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Becotatug vedotin · Pucotenlimab

Start the discussion